Treating hepatitis C in methadone maintenance patients: an interim analysis.

[1]  G. Davis,et al.  Treatment of chronic hepatitis C in active drug users. , 2001, The New England journal of medicine.

[2]  K. Seal,et al.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? , 2001, The New England journal of medicine.

[3]  Jian Yu,et al.  Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study , 2001 .

[4]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[5]  N. Flynn,et al.  Hepatitis C in Methadone Maintenance Patients , 2001, Journal of addictive diseases.

[6]  Huy A. Nguyen,et al.  Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population , 2001, American Journal of Gastroenterology.

[7]  E. Heathcote,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[8]  Huy A. Nguyen,et al.  Influence of psychiatric diagnoses on alpha-interferon treatment in a veteran population with chronic hepatitis C , 2000 .

[9]  Sanjeev Arora,et al.  Clinical features of hepatitis C–infected patients with persistently normal alanine transaminase levels in the southwestern United States , 1999, Hepatology.

[10]  William M. Lee,et al.  Racial differences in responses to therapy with interferon in chronic hepatitis C , 1999, Hepatology.

[11]  H. Margolis,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[12]  C. Pariante,et al.  Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders , 1999, The Lancet.

[13]  O. Weiland,et al.  Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. , 1999, Journal of hepatology.

[14]  S. Issa,et al.  Liver transplantation for chronic viral hepatitis. , 1999, The Surgical clinics of North America.

[15]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[16]  L. Kalish,et al.  Hepatitis C Virus Infection in Chicago Women With or at Risk for HIV Infection: Evidence for Sexual Transmission , 1998, Sexually transmitted diseases.

[17]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[18]  H. Margolis,et al.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .

[19]  D. V. van Thiel,et al.  Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. , 1998, Hepato-gastroenterology.

[20]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[21]  D. Vlahov,et al.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. , 1996, American journal of public health.

[22]  D. V. van Thiel,et al.  Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. , 1995, European journal of gastroenterology & hepatology.

[23]  D. Vlahov,et al.  Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. , 1991, American journal of epidemiology.

[24]  J. Hoofnagle,et al.  The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. , 1991, The American journal of gastroenterology.

[25]  M. Buti,et al.  HEPATITIS C VIRUS ANTIBODIES AMONG RISK GROUPS IN SPAIN , 1989, The Lancet.

[26]  N. Chiorazzi,et al.  Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. , 1989, The Journal of pharmacology and experimental therapeutics.

[27]  M. Weissman,et al.  Assessing depressive symptoms in five psychiatric populations: a validation study. , 1977, American journal of epidemiology.

[28]  V. Schuermans,et al.  IMPAIRED NEUTROPHIL PHAGOCYTOSIS , 1974 .

[29]  J. Duchin,et al.  Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.

[30]  N. Flynn,et al.  Seroepidemiology of viral infections among intravenous drug users in northern California. , 1992, The Western journal of medicine.

[31]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .